These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26876225)

  • 1. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.
    Dunbar RL; Goel H
    Curr Atheroscler Rep; 2016 Feb; 18(2):11. PubMed ID: 26876225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics.
    Goel H; Dunbar RL
    Curr Atheroscler Rep; 2016 Apr; 18(4):17. PubMed ID: 26932224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
    Chrysant SG; Ibrahim M
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyslipidaemia: cardiovascular prevention--end of the road for niacin?
    Tuteja S; Rader DJ
    Nat Rev Endocrinol; 2014 Nov; 10(11):646-7. PubMed ID: 25178730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.
    Kent S; Haynes R; Hopewell JC; Parish S; Gray A; Landray MJ; Collins R; Armitage J; Mihaylova B;
    Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):348-54. PubMed ID: 27407053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
    Pandian A; Arora A; Sperling LS; Khan BV
    Vasc Health Risk Manag; 2008; 4(5):1001-9. PubMed ID: 19183748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
    Kones R; Rumana U
    Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia.
    Gupta EK; Ito MK
    Heart Dis; 2002; 4(2):124-37. PubMed ID: 11975844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niacin, an old drug with a new twist.
    Song WL; FitzGerald GA
    J Lipid Res; 2013 Oct; 54(10):2586-94. PubMed ID: 23948546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
    McKenney JM
    Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidaemia: Failure to THRIVE: the end for niacin?
    Wierzbicki AS
    Nat Rev Cardiol; 2013 May; 10(5):246-7. PubMed ID: 23546446
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of niacin on glucose control in patients with dyslipidemia.
    Goldberg RB; Jacobson TA
    Mayo Clin Proc; 2008 Apr; 83(4):470-8. PubMed ID: 18380993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects of niacin: Current possibilities for its clinical use.
    Zeman M; Vecka M; Perlík F; Staňková B; Hromádka R; Tvrzická E; Širc J; Hrib J; Žák A
    Acta Pharm; 2016 Dec; 66(4):449-469. PubMed ID: 27749252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
    Robinson JG
    Vasc Health Risk Manag; 2009; 5(1):31-43. PubMed ID: 19436666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.